Robert B Diasio

Robert B Diasio

UNVERIFIED PROFILE

Are you Robert B Diasio?   Register this Author

Register author
Robert B Diasio

Robert B Diasio

Publications by authors named "Robert B Diasio"

Are you Robert B Diasio?   Register this Author

90Publications

1681Reads

19Profile Views

Optimal Lymph Node Examination and Adjuvant Chemotherapy for Stage I Lung Cancer.

J Thorac Oncol 2019 Jul 19;14(7):1277-1285. Epub 2019 Apr 19.

Department of Thoracic Surgery, Shanghai Pulmonary Hospital Tongji University, Shanghai, People's Republic of China. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15560864193029
Publisher Site
http://dx.doi.org/10.1016/j.jtho.2019.03.027DOI Listing
July 2019

T4 extension alone is more predictive of better survival than a tumour size >7 cm for resected T4N0-1M0 non-small-cell lung cancer†.

Eur J Cardiothorac Surg 2019 Apr;55(4):682-690

Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University, Shanghai, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ejcts/ezy360DOI Listing
April 2019

Gene-Specific Variant Classifier (DPYD-Varifier) to Identify Deleterious Alleles of Dihydropyrimidine Dehydrogenase.

Clin Pharmacol Ther 2018 10 2;104(4):709-718. Epub 2018 Feb 2.

Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cpt.1020DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6043412PMC
October 2018

Histone H3K27 Trimethylation Modulates 5-Fluorouracil Resistance by Inhibiting PU.1 Binding to the DPYD Promoter.

Cancer Res 2016 11 30;76(21):6362-6373. Epub 2016 Aug 30.

Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic Cancer Center, Rochester, Minnesota.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-16-1306DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5093042PMC
November 2016

Benefit of uridine triacetate (Vistogard) in rescuing severe 5-fluorouracil toxicity in patients with dihydropyrimidine dehydrogenase (DPYD) deficiency.

Cancer Chemother Pharmacol 2016 Jul 8;78(1):151-6. Epub 2016 Jun 8.

Mayo Clinic, Rochester, MN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-016-3063-1DOI Listing
July 2016

Current insights into the impact of dihydropyrimidine dehydrogenase deficiency in patients receiving treatment with 5-fluorouracil.

Authors:
Robert B Diasio

Clin Adv Hematol Oncol 2016 Jul;14(7):510-2

Mayo Clinic Cancer Center, College of Medicine, Rochester, Minnesota.

View Article

Download full-text PDF

Source
July 2016

Value, Access, and Cost of Cancer Care Delivery at Academic Cancer Centers.

J Natl Compr Canc Netw 2016 07;14(7):837-47

From National Comprehensive Cancer Network, Fort Washington, Pennsylvania; University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama; City of Hope Comprehensive Cancer Center, Los Angeles, California; Mayo Clinic Cancer Center, Rochester, Minnesota; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio; UC San Diego Moores Cancer Center, La Jolla, California; Patient, City of Hope Comprehensive Cancer Center, Los Angeles, California; and Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2016.0088DOI Listing
July 2016

Drug metabolism and pancreatic cancer.

Ann Gastroenterol 2017 21;30(1):54-61. Epub 2016 Jul 21.

Division of Hematology/Oncology and Experimental Therapeutics, Tufts Medical Center, Boston, MA (John Paul E. Flores, Muhammad Wasif Saif).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.20524/aog.2016.0074DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5198247PMC
July 2016

Biomarkers of Fluorouracil Toxicity: Insight From the PETACC-8 Trial.

JAMA Oncol 2016 May;2(5):662-663

Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota2Mayo Clinic College of Medicine, Mayo Clinic, Rochester, Minnesota3Department of Oncology, Mayo Clinic, Rochester, Minnesota4Mayo Clinic Cancer Center, R.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2015.5463DOI Listing
May 2016

Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance).

Pharmacogenet Genomics 2016 Mar;26(3):133-7

aDepartment of Molecular Pharmacology and Experimental Therapeutics (MPET), Mayo Clinic Cancer Center bAlliance Statistics and Data Center cDivision of Medical Oncology dDivision of Gastroenterology, Mayo Clinic, Rochester, Minnesota eDepartment of Surgery, Cancer Prevention and Control Program, University of Hawaii Cancer Center, Honolulu, Hawaii fDepartment of Medicine, Center for GI Oncology, The University of Chicago Medicine, Chicago, Illinois gDivision of Hematology Oncology, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee hSurgical Oncology Associates of South Texas, San Antonio, Texas iDepartment of Hematology Oncology, Lehigh Valley Health Network, John and Dorthy Morgan Cancer Center, Allentown, Pennsylvania jDepartment of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, Michigan kDepartment of Hematology/Oncology, Division of Medical Oncology, The Ohio State University Medical Center, Columbus, Ohio, USA lDepartment of Medicine, Division of Medical Oncology, University of British Columbia, British Columbia Cancer Agency, Vancouver, British Columbia, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FPC.0000000000000197DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4738010PMC
March 2016

Is It Finally Time for a Personalized Medicine Approach for Fluorouracil-Based Therapies?

J Clin Oncol 2016 Jan 7;34(3):205-7. Epub 2015 Dec 7.

Mayo Clinic, Rochester, MN

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.64.2546DOI Listing
January 2016

Acquired factor VII deficiency following FOLFOX in a patient with colorectal cancer who was also DPD deficient.

Therap Adv Gastroenterol 2016 Jan;9(1):121-7

Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1756283X15604115DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4699273PMC
January 2016

Polymorphisms in MIR27A Associated with Early-Onset Toxicity in Fluoropyrimidine-Based Chemotherapy.

Clin Cancer Res 2015 May 5;21(9):2038-44. Epub 2015 Feb 5.

University Institute of Clinical Chemistry, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-2817DOI Listing
May 2015

DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147).

J Natl Cancer Inst 2014 Dec 7;106(12). Epub 2014 Nov 7.

Department of Molecular Pharmacology and Experimental Therapeutics (AML, RBD), Alliance Statistics and Data Center (QS, EP, DJS), Division of Medical Oncology (SRA, FAS, RBD), Division of Gastroenterology (FAS), Mayo Clinic Cancer Center, Rochester, MN; Cancer Prevention and Control Program, University of Hawaii Cancer Center, Honolulu, HI (JLB); Division of Medical Oncology, The Ohio State University Medical Center, Columbus, OH (RMG).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/dju298DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4271081PMC
December 2014

Association study of the let-7 miRNA-complementary site variant in the 3' untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 Clinical Trial).

Clin Cancer Res 2014 Jun 11;20(12):3319-27. Epub 2014 Apr 11.

Authors' Affiliations: Department of Molecular Pharmacology and Experimental Therapeutics (MPET); Alliance Statistics and Data Center; Division of Medical Oncology; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota; and Department of Medical Oncology, Shandong Provincial Hospital Affiliated to Shandong University, Ji'nan, Shandong Province, ChinaAuthors' Affiliations: Department of Molecular Pharmacology and Experimental Therapeutics (MPET); Alliance Statistics and Data Center; Division of Medical Oncology; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota; and Department of Medical Oncology, Shandong Provincial Hospital Affiliated to Shandong University, Ji'nan, Shandong Province, China

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-0069DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4084689PMC
June 2014

Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity.

Cancer Res 2014 May 19;74(9):2545-54. Epub 2014 Mar 19.

Authors' Affiliations: Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Mayo Clinic Cancer Center, Mayo Clinic, Rochester, Minnesota; and Paracelsus Medical University, Salzburg, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-13-2482DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4012613PMC
May 2014

Genetic biomarkers for Fluorouracil toxicity prediction: the long road to clinical utility.

J Clin Oncol 2014 Apr 3;32(10):989-90. Epub 2014 Mar 3.

Mayo Clinic, Rochester, MN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.53.4479DOI Listing
April 2014

microRNAs miR-27a and miR-27b directly regulate liver dihydropyrimidine dehydrogenase expression through two conserved binding sites.

Mol Cancer Ther 2014 Mar 8;13(3):742-51. Epub 2014 Jan 8.

Corresponding Author: Robert B. Diasio, Mayo Clinic Cancer Center, 200 1st Street Southwest, Rochester, MN 55905.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-13-0878DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3954441PMC
March 2014

Phenotypic profiling of DPYD variations relevant to 5-fluorouracil sensitivity using real-time cellular analysis and in vitro measurement of enzyme activity.

Cancer Res 2013 Mar 17;73(6):1958-68. Epub 2013 Jan 17.

Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic Cancer Center, Rochester, Minnesota 55905, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-12-3858DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3602211PMC
March 2013

A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11.

Authors:
Afshan Siddiq Fergus J Couch Gary K Chen Sara Lindström Diana Eccles Robert C Millikan Kyriaki Michailidou Daniel O Stram Lars Beckmann Suhn Kyong Rhie Christine B Ambrosone Kristiina Aittomäki Pilar Amiano Carmel Apicella Laura Baglietto Elisa V Bandera Matthias W Beckmann Christine D Berg Leslie Bernstein Carl Blomqvist Hiltrud Brauch Louise Brinton Quang M Bui Julie E Buring Saundra S Buys Daniele Campa Jane E Carpenter Daniel I Chasman Jenny Chang-Claude Constance Chen Françoise Clavel-Chapelon Angela Cox Simon S Cross Kamila Czene Sandra L Deming Robert B Diasio W Ryan Diver Alison M Dunning Lorraine Durcan Arif B Ekici Peter A Fasching Heather Spencer Feigelson Laura Fejerman Jonine D Figueroa Olivia Fletcher Dieter Flesch-Janys Mia M Gaudet Susan M Gerty Jorge L Rodriguez-Gil Graham G Giles Carla H van Gils Andrew K Godwin Nikki Graham Dario Greco Per Hall Susan E Hankinson Arndt Hartmann Rebecca Hein Judith Heinz Robert N Hoover John L Hopper Jennifer J Hu Scott Huntsman Sue A Ingles Astrid Irwanto Claudine Isaacs Kevin B Jacobs Esther M John Christina Justenhoven Rudolf Kaaks Laurence N Kolonel Gerhard A Coetzee Mark Lathrop Loic Le Marchand Adam M Lee I-Min Lee Timothy Lesnick Peter Lichtner Jianjun Liu Eiliv Lund Enes Makalic Nicholas G Martin Catriona A McLean Hanne Meijers-Heijboer Alfons Meindl Penelope Miron Kristine R Monroe Grant W Montgomery Bertram Müller-Myhsok Stefan Nickels Sarah J Nyante Curtis Olswold Kim Overvad Domenico Palli Daniel J Park Julie R Palmer Harsh Pathak Julian Peto Paul Pharoah Nazneen Rahman Fernando Rivadeneira Daniel F Schmidt Rita K Schmutzler Susan Slager Melissa C Southey Kristen N Stevens Hans-Peter Sinn Michael F Press Eric Ross Elio Riboli Paul M Ridker Fredrick R Schumacher Gianluca Severi Isabel Dos Santos Silva Jennifer Stone Malin Sund William J Tapper Michael J Thun Ruth C Travis Clare Turnbull Andre G Uitterlinden Quinten Waisfisz Xianshu Wang Zhaoming Wang Joellen Weaver Rüdiger Schulz-Wendtland Lynne R Wilkens David Van Den Berg Wei Zheng Regina G Ziegler Elad Ziv Heli Nevanlinna Douglas F Easton David J Hunter Brian E Henderson Stephen J Chanock Montserrat Garcia-Closas Peter Kraft Christopher A Haiman Celine M Vachon

Hum Mol Genet 2012 Dec 13;21(24):5373-84. Epub 2012 Sep 13.

Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.

View Article

Download full-text PDF

Source
https://academic.oup.com/hmg/article/21/24/5373/665552
Publisher Site
http://dx.doi.org/10.1093/hmg/dds381DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3510753PMC
December 2012

Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas.

Clin Cancer Res 2012 Jan;18(2):546-54

Departments of Medical Oncology, Health Sciences Research, Cytogenetics, Anatomic Pathology, Cancer Center, Laboratory Medicine and Pathology, and Gastroenterology, Mayo Clinic, Rochester, MN 55905, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-11-2272DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3261584PMC
January 2012

Common breast cancer susceptibility loci are associated with triple-negative breast cancer.

Cancer Res 2011 Oct 15;71(19):6240-9. Epub 2011 Aug 15.

Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota 55905, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-11-1266DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3327299PMC
October 2011

A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer.

Authors:
Christopher A Haiman Gary K Chen Celine M Vachon Federico Canzian Alison Dunning Robert C Millikan Xianshu Wang Foluso Ademuyiwa Shahana Ahmed Christine B Ambrosone Laura Baglietto Rosemary Balleine Elisa V Bandera Matthias W Beckmann Christine D Berg Leslie Bernstein Carl Blomqvist William J Blot Hiltrud Brauch Julie E Buring Lisa A Carey Jane E Carpenter Jenny Chang-Claude Stephen J Chanock Daniel I Chasman Christine L Clarke Angela Cox Simon S Cross Sandra L Deming Robert B Diasio Athanasios M Dimopoulos W Ryan Driver Thomas Dünnebier Lorraine Durcan Diana Eccles Christopher K Edlund Arif B Ekici Peter A Fasching Heather S Feigelson Dieter Flesch-Janys Florentia Fostira Asta Försti George Fountzilas Susan M Gerty Graham G Giles Andrew K Godwin Paul Goodfellow Nikki Graham Dario Greco Ute Hamann Susan E Hankinson Arndt Hartmann Rebecca Hein Judith Heinz Andrea Holbrook Robert N Hoover Jennifer J Hu David J Hunter Sue A Ingles Astrid Irwanto Jennifer Ivanovich Esther M John Nicola Johnson Arja Jukkola-Vuorinen Rudolf Kaaks Yon-Dschun Ko Laurence N Kolonel Irene Konstantopoulou Veli-Matti Kosma Swati Kulkarni Diether Lambrechts Adam M Lee Loïc Le Marchand Timothy Lesnick Jianjun Liu Sara Lindstrom Arto Mannermaa Sara Margolin Nicholas G Martin Penelope Miron Grant W Montgomery Heli Nevanlinna Stephan Nickels Sarah Nyante Curtis Olswold Julie Palmer Harsh Pathak Dimitrios Pectasides Charles M Perou Julian Peto Paul D P Pharoah Loreall C Pooler Michael F Press Katri Pylkäs Timothy R Rebbeck Jorge L Rodriguez-Gil Lynn Rosenberg Eric Ross Thomas Rüdiger Isabel dos Santos Silva Elinor Sawyer Marjanka K Schmidt Rüdiger Schulz-Wendtland Fredrick Schumacher Gianluca Severi Xin Sheng Lisa B Signorello Hans-Peter Sinn Kristen N Stevens Melissa C Southey William J Tapper Ian Tomlinson Frans B L Hogervorst Els Wauters JoEllen Weaver Hans Wildiers Robert Winqvist David Van Den Berg Peggy Wan Lucy Y Xia Drakoulis Yannoukakos Wei Zheng Regina G Ziegler Afshan Siddiq Susan L Slager Daniel O Stram Douglas Easton Peter Kraft Brian E Henderson Fergus J Couch

Nat Genet 2011 Oct 30;43(12):1210-4. Epub 2011 Oct 30.

Department of Preventive Medicine, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ng.985DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3279120PMC
October 2011

A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population.

Authors:
Antonis C Antoniou Xianshu Wang Zachary S Fredericksen Lesley McGuffog Robert Tarrell Olga M Sinilnikova Sue Healey Jonathan Morrison Christiana Kartsonaki Timothy Lesnick Maya Ghoussaini Daniel Barrowdale Susan Peock Margaret Cook Clare Oliver Debra Frost Diana Eccles D Gareth Evans Ros Eeles Louise Izatt Carol Chu Fiona Douglas Joan Paterson Dominique Stoppa-Lyonnet Claude Houdayer Sylvie Mazoyer Sophie Giraud Christine Lasset Audrey Remenieras Olivier Caron Agnès Hardouin Pascaline Berthet Frans B L Hogervorst Matti A Rookus Agnes Jager Ans van den Ouweland Nicoline Hoogerbrugge Rob B van der Luijt Hanne Meijers-Heijboer Encarna B Gómez García Peter Devilee Maaike P G Vreeswijk Jan Lubinski Anna Jakubowska Jacek Gronwald Tomasz Huzarski Tomasz Byrski Bohdan Górski Cezary Cybulski Amanda B Spurdle Helene Holland David E Goldgar Esther M John John L Hopper Melissa Southey Saundra S Buys Mary B Daly Mary-Beth Terry Rita K Schmutzler Barbara Wappenschmidt Christoph Engel Alfons Meindl Sabine Preisler-Adams Norbert Arnold Dieter Niederacher Christian Sutter Susan M Domchek Katherine L Nathanson Timothy Rebbeck Joanne L Blum Marion Piedmonte Gustavo C Rodriguez Katie Wakeley John F Boggess Jack Basil Stephanie V Blank Eitan Friedman Bella Kaufman Yael Laitman Roni Milgrom Irene L Andrulis Gord Glendon Hilmi Ozcelik Tomas Kirchhoff Joseph Vijai Mia M Gaudet David Altshuler Candace Guiducci Niklas Loman Katja Harbst Johanna Rantala Hans Ehrencrona Anne-Marie Gerdes Mads Thomassen Lone Sunde Paolo Peterlongo Siranoush Manoukian Bernardo Bonanni Alessandra Viel Paolo Radice Trinidad Caldes Miguel de la Hoya Christian F Singer Anneliese Fink-Retter Mark H Greene Phuong L Mai Jennifer T Loud Lucia Guidugli Noralane M Lindor Thomas V O Hansen Finn C Nielsen Ignacio Blanco Conxi Lazaro Judy Garber Susan J Ramus Simon A Gayther Catherine Phelan Stephen Narod Csilla I Szabo Javier Benitez Ana Osorio Heli Nevanlinna Tuomas Heikkinen Maria A Caligo Mary S Beattie Ute Hamann Andrew K Godwin Marco Montagna Cinzia Casella Susan L Neuhausen Beth Y Karlan Nadine Tung Amanda E Toland Jeffrey Weitzel Olofunmilayo Olopade Jacques Simard Penny Soucy Wendy S Rubinstein Adalgeir Arason Gad Rennert Nicholas G Martin Grant W Montgomery Jenny Chang-Claude Dieter Flesch-Janys Hiltrud Brauch Gianluca Severi Laura Baglietto Angela Cox Simon S Cross Penelope Miron Sue M Gerty William Tapper Drakoulis Yannoukakos George Fountzilas Peter A Fasching Matthias W Beckmann Isabel Dos Santos Silva Julian Peto Diether Lambrechts Robert Paridaens Thomas Rüdiger Asta Försti Robert Winqvist Katri Pylkäs Robert B Diasio Adam M Lee Jeanette Eckel-Passow Celine Vachon Fiona Blows Kristy Driver Alison Dunning Paul P D Pharoah Kenneth Offit V Shane Pankratz Hakon Hakonarson Georgia Chenevix-Trench Douglas F Easton Fergus J Couch

Nat Genet 2010 Oct 19;42(10):885-92. Epub 2010 Sep 19.

Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ng.669DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3130795PMC
October 2010

ADAM-17: a target to increase chemotherapeutic efficacy in colorectal cancer?

Clin Cancer Res 2010 Jul 22;16(13):3319-21. Epub 2010 Jun 22.

Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota 55905, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-10-1059DOI Listing
July 2010

(13)C-5-FU breath test current status and future directions: a comprehensive review.

J Breath Res 2009 Dec 27;3(4):047002. Epub 2009 Nov 27.

Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1088/1752-7155/3/4/047002DOI Listing
December 2009

Histone deacetylase inhibitors: current status and overview of recent clinical trials.

Drugs 2009 Oct;69(14):1911-34

Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota 55905, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2165/11315680-000000000-00000DOI Listing
October 2009

Prognostication of pancreatic adenocarcinoma by expression of thymidine phosphorylase/dihydropyrimidine dehydrogenase ratio and its correlation with survival.

Expert Opin Drug Saf 2009 Sep;8(5):507-14

Yale University School of Medicine, Yale Cancer Center, Section of Medical Oncology, 333 Cedar Street; FMP: 116, New Haven, CT 06520, USA.

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/full/10.1517/1474033090317321
Publisher Site
http://dx.doi.org/10.1517/14740330903173217DOI Listing
September 2009

Genetic regulation of beta-ureidopropionase and its possible implication in altered uracil catabolism.

Pharmacogenet Genomics 2008 Jan;18(1):25-35

Division of Clinical Pharmacology and Toxicology, University of Alabama at Birmingham, Alabama, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FPC.0b013e3282f2f134DOI Listing
January 2008

Capecitabine-related cardiotoxicity: recognition and management.

J Support Oncol 2008 Jan;6(1):41-8

Yale University School of Medicine, Section of Medical Oncology, New Haven, CT 06520, USA.

View Article

Download full-text PDF

Source
January 2008

Genetic regulation of dihydropyrimidinase and its possible implication in altered uracil catabolism.

Pharmacogenet Genomics 2007 Nov;17(11):973-87

Division of Clinical Pharmacology and Toxicology, University of Alabama at Birmingham, Alabama, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FPC.0b013e3282f01788DOI Listing
November 2007

DPYD*2A mutation: the most common mutation associated with DPD deficiency.

Cancer Chemother Pharmacol 2007 Sep 13;60(4):503-7. Epub 2006 Dec 13.

Yale University School of Medicine, Section of Medical Oncology, 333 Cedar Street; FMP 116, New Haven, CT 06520, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-006-0392-5DOI Listing
September 2007

Regulation of human dihydropyrimidine dehydrogenase: implications in the pharmacogenetics of 5-FU-based chemotherapy.

Pharmacogenomics 2007 Mar;8(3):257-65

University of Alabama, Department of Pharmacology and Toxicology, Birmingham, AL 35294, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/14622416.8.3.257DOI Listing
March 2007

DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY (DPD) IN GI MALIGNANCIES: EXPERIENCE OF 4-YEARS.

Pak J Med Sci 2007 ;23(6):832-839

Yale University School of Medicine, New Haven, CT Athens Medical School, Sotiria General Hospital, Athens, Greece.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2563423PMC
January 2007

Targeting the epidermal growth factor receptor in the treatment of colorectal cancer: state of the art.

Drugs 2006 ;66(11):1441-63

Departments of Medicine, Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama 35294-0019, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2165/00003495-200666110-00003DOI Listing
December 2006

Peripheral neuropathy exacerbation associated with topical 5-fluorouracil.

Anticancer Drugs 2006 Oct;17(9):1095-8

Section of Medical Oncology, Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut 06520, USA.

View Article

Download full-text PDF

Source
http://pdfs.journals.lww.com/anti-cancerdrugs/2006/10000/Per
Web Search
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:land
Publisher Site
http://dx.doi.org/10.1097/01.cad.0000231479.30524.0eDOI Listing
October 2006

Dihydropyrimidine dehydrogenase deficiency in an Indian population.

Cancer Chemother Pharmacol 2006 Sep 19;58(3):396-401. Epub 2006 Jan 19.

Yale University School of Medicine, New Haven, CT 06520, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-005-0174-5DOI Listing
September 2006

Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians.

Clin Cancer Res 2006 Sep;12(18):5491-5

Division of Clinical Pharmacology and Toxicology, Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama 35294-3300, USA.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-06-0747DOI Listing
September 2006

Genetic testing in cancer therapeutics.

Clin Cancer Res 2006 Jul;12(14 Pt 1):4137-41

Department of Pharmacology and Toxicology, Division of Clinical Pharmacology, and Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama 35294-3300, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-06-0707DOI Listing
July 2006

The role of Sp1 and Sp3 in the constitutive DPYD gene expression.

Biochim Biophys Acta 2006 May 16;1759(5):247-56. Epub 2006 May 16.

Department of Environmental Health Sciences, University of Alabama at Birmingham, Birmingham, AL 35294, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbaexp.2006.05.001DOI Listing
May 2006

The uracil breath test in the assessment of dihydropyrimidine dehydrogenase activity: pharmacokinetic relationship between expired 13CO2 and plasma [2-13C]dihydrouracil.

Clin Cancer Res 2006 Jan;12(2):549-55

Division of Clinical Pharmacology and Toxicology, Comprehensive Cancer Center, University of Alabama at Birmingham, 1824 6th Avenue South, Birmingham, AL 35294, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-05-2020DOI Listing
January 2006

Advances and challenges in fluoropyrimidine pharmacogenomics and pharmacogenetics.

Pharmacogenomics 2005 Dec;6(8):835-47

National University of Singapore, Oncology Research Institute and Department of Pathology, 10 Medical Drive, MD11 Level 5, Singapore 117597, Republic of Singapore.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/14622416.6.8.835DOI Listing
December 2005

Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients.

Clin Cancer Res 2005 Dec;11(24 Pt 1):8699-705

Division of Clinical Pharmacology and Toxicology, Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama 35294-3300, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-05-1520DOI Listing
December 2005

Edotecarin: a novel topoisomerase I inhibitor.

Clin Colorectal Cancer 2005 May;5(1):27-36

Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL 35294-3300, USA.

View Article

Download full-text PDF

Source
May 2005

Perspectives in the treatment of colorectal cancer.

Semin Oncol 2004 Dec;31(6 Suppl 15):14-8

OU Cancer Center, University of Oklahoma, Oklahoma City 73190, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2004.11.023DOI Listing
December 2004

Selecting regimens in advanced colon cancer.

Authors:
Robert B Diasio

J Natl Compr Canc Netw 2004 Sep;2 Suppl 3:S-19-24

University of Alabama at Birmingham, 1670 University Boulevard, VH L108H, Birmingham, AL 35294-0019, USA.

View Article

Download full-text PDF

Source
September 2004

Peripheral neuropathy associated with capecitabine.

Anticancer Drugs 2004 Sep;15(8):767-71

University of Alabama at Birmingham, Comprehensive Cancer Center, Birmingham, AL 35294-3300, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/00001813-200409000-00005DOI Listing
September 2004

Rapid identification of dihydropyrimidine dehydrogenase deficiency by using a novel 2-13C-uracil breath test.

Clin Cancer Res 2004 Apr;10(8):2652-8

University of Alabama at Birmingham, Division of Clinical Pharmacology and Toxicology, 35294, USA.

View Article

Download full-text PDF

Source
April 2004

Dihydropyrimidine dehydrogenase (DPD) rapidly regenerates after inactivation by eniluracil (GW776C85) in primary and metastatic colorectal cancer.

Cancer Chemother Pharmacol 2003 Nov 7;52(5):399-404. Epub 2003 Aug 7.

Department of Surgery, University of Alabama at Birmingham, 1922 Seventh Ave South, Birmingham, AL 35294, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-003-0681-1DOI Listing
November 2003

Capecitabine induces rapid, sustained response in two patients with extensive oral verrucous carcinoma.

Clin Cancer Res 2003 Feb;9(2):580-5

Lombardi Cancer Center, Georgetown University, Washington DC 20007, USA.

View Article

Download full-text PDF

Source
February 2003

Induction of thymidine phosphorylase in both irradiated and shielded, contralateral human U87MG glioma xenografts: implications for a dual modality treatment using capecitabine and irradiation.

Mol Cancer Ther 2002 Oct;1(12):1139-45

Departments of Pharmacology and Toxicology, Division of Clinical Pharmacology, Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL 35294-3300, USA.

View Article

Download full-text PDF

Source
October 2002

A high-throughput denaturing high-performance liquid chromatography method for the identification of variant alleles associated with dihydropyrimidine dehydrogenase deficiency.

Anal Biochem 2002 Jul;306(1):63-73

Division of Clinical Pharmacology, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1006/abio.2002.5666DOI Listing
July 2002

Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics.

Pharmacogenomics 2002 Jul;3(4):485-92

Department of Pharmacology and Toxicology, Room 101, Volker Hall, University of Alabama at Birmingham, Birmingham, AL 35294, USA.

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/abs/10.1517/14622416.3.4.
Publisher Site
http://dx.doi.org/10.1517/14622416.3.4.485DOI Listing
July 2002

Can eniluracil improve 5-fluorouracil therapy?

Authors:
Robert B Diasio

Clin Colorectal Cancer 2002 May;2(1):53

Departments of Pharmacology/Toxicology and Medicine, Comprehensive Cancer Center, University of Alabama at Birmingham, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1533-0028(11)70503-5DOI Listing
May 2002

Housekeeping gene variability in normal and carcinomatous colorectal and liver tissues: applications in pharmacogenomic gene expression studies.

Anal Biochem 2002 Apr;303(2):209-14

Division of Clinical Pharmacology, Department of Pharmacology and Toxicology, Comprehensive Cancer Center, University of Alabama at Birmingham, 35294, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1006/abio.2001.5570DOI Listing
April 2002

A comparative analysis of translated dihydropyrimidine dehydrogenase cDNA; conservation of functional domains and relevance to genetic polymorphisms.

Pharmacogenetics 2002 Mar;12(2):133-44

Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA.

View Article

Download full-text PDF

Source
March 2002

Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype.

Clin Cancer Res 2002 Mar;8(3):768-74

Department of Pharmacology and Toxicology and Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA.

View Article

Download full-text PDF

Source
March 2002

An evolving role for oral fluoropyrimidine drugs.

Authors:
Robert B Diasio

J Clin Oncol 2002 Feb;20(4):894-6

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2002.20.4.894DOI Listing
February 2002